Small Molecules for Active Targeting in Cancer

被引:111
作者
Kue, Chin S. [1 ]
Kamkaew, Anyanee [2 ]
Burgess, Kevin [2 ]
Kiew, Lik V. [1 ]
Chung, Lip Y. [3 ]
Lee, Hong B. [3 ]
机构
[1] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia
[2] Texas A&M Univ, Dept Chem, Box 30012, College Stn, TX 77842 USA
[3] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia
关键词
drug delivery; active targeting; cancer therapeutics; cancer imaging; small-molecule ligands; CARBONIC-ANHYDRASE-IX; MEMBRANE ANTIGEN PSMA; PHASE-II TRIAL; CHOLECYSTOKININ-B/GASTRIN RECEPTORS; PEPTIDE-PACLITAXEL CONJUGATE; METHYL-BETA-CYCLODEXTRIN; CELL LUNG-CANCER; FOLATE-RECEPTOR; ESTROGEN-RECEPTOR; BIOLOGICAL EVALUATION;
D O I
10.1002/med.21387
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
For the purpose of this review, active targeting in cancer research encompasses strategies wherein a ligand for a cell surface receptor expressed on tumor cells is used to deliver a cytotoxic or imaging cargo. This area of research is more than two decades old, but in those 20 and more years, how many receptors have been studied extensively? What kinds of the ligands are used for active targeting? Are they mostly naturally occurring molecules such as folic acid, or synthetic substances developed in campaigns for medicinal chemistry efforts? This review outlines the most important receptor or ligand combinations that have been used in active targeting to answer these questions, and therefore to address the most important one of all: is research in active targeting affording diminishing returns, or is this an area for which the potential far exceeds progress made so far?
引用
收藏
页码:494 / 575
页数:82
相关论文
共 352 条
  • [1] A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
    Abraham, Jame
    Edgerly, Maureen
    Wilson, Richard
    Chen, Clara
    Rutt, Ann
    Bakke, Susan
    Robey, Rob
    Dwyer, Andrew
    Goldspiel, Barry
    Balis, Frank
    Van Tellingen, Olaf
    Bates, Susan E.
    Fojo, Tito
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (10) : 3574 - 3582
  • [2] Adams GP, 2001, CANCER RES, V61, P4750
  • [3] Targeted cancer therapies
    Aggarwal, Saurabh
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) : 427 - 428
  • [4] Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells
    Al-Nabulsi, I
    Mach, RH
    Wang, LM
    Wallen, CA
    Keng, PC
    Sten, K
    Childers, SR
    Wheeler, KT
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (06) : 925 - 933
  • [5] Factors affecting the clearance and biodistribution of polymeric nanoparticles
    Alexis, Frank
    Pridgen, Eric
    Molnar, Linda K.
    Farokhzad, Omid C.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (04) : 505 - 515
  • [6] Camptothecins in tumor homing via an RGD sequence mimetic
    Alloatti, Domenico
    Giannini, Giuseppe
    Vesci, Loredana
    Castorina, Massimo
    Pisano, Claudio
    Badaloni, Elena
    Cabri, Walter
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (20) : 6509 - 6512
  • [7] A Phase I/Ib Study of Folate Immune (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) With Interferon-α and Interleukin-2 in Patients With Renal Cell Carcinoma
    Amato, Robert J.
    Shetty, Aditya
    Lu, Yingjuan
    Ellis, P. Ron
    Mohlere, Virginia
    Carnahan, Natalie
    Low, Philip S.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2014, 37 (04) : 237 - 244
  • [8] A Phase I Study of Folate Immune Therapy (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) in Patients With Renal Cell Carcinoma
    Amato, Robert J.
    Shetty, Aditya
    Lu, Yingjuan
    Ellis, Ron
    Low, Philip S.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2013, 36 (04) : 268 - 275
  • [9] Biochemical, cellular, and pharmacological aspects of the multidrug transporter
    Ambudkar, SV
    Dey, S
    Hrycyna, CA
    Ramachandra, M
    Pastan, I
    Gottesman, MM
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 : 361 - 398
  • [10] Drug delivery systems for oestrogenic hormones and antagonists: the need for selective targeting in estradiol-dependent cancers
    Ameller, T
    Legrand, P
    Marsaud, V
    Renoir, JM
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 92 (1-2) : 1 - 18